Past Event: Launching The Lancet Oncology Commission on Future Cancer Research Priorities in the USA

Immunotherapy: Precision Medicine in Action The importance of keeping the promise and potential of immunotherapy alive

The first cancer immunotherapy was approved in 2011; today, there are more than 70 such drugs in the clinical pipeline. By 2020, the cancer treatment industry is expected to achieve $16.55 billion dollars in revenue. Read our policy brief to learn more about milestones in cancer immunotherapy.

Hear from top scientists on how they recommend expanding and implementing the Blue Ribbon Panel’s road map for cancer research. They’ll discuss a report that will be published by the journal The Lancet Oncology and is co-edited by Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, and Chi Van Dang, M.D., Ph.D., scientific director at Ludwig Cancer Research and professor at The Wistar Institute. Learn what you need to know about investing in research, prevention and treatment of cancer, the second leading cause of death in the U.S. Reserve your attendance now by emailing JHontheRoad@jhmi.edu

Wednesday, November 1, from 8:30 a.m. to 12:00 p.m.
Capitol Hill Hart Senate Office Building, Room 902
120 Constitution Avenue NE, Washington, D.C. 20002
  

Speakers

Paul Rothman, M.D.
Dean of the Medical Faculty
CEO, Johns Hopkins Medicine

David Collingridge, Ph.D.
Editor-in-Chief, The Lancet Oncology

Elizabeth Jaffee, M.D.
Professor of Oncology and Deputy Director, Johns Hopkins Sidney Kimmel Cancer Center
Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy

Chi Van Dang, M.D., Ph.D.
Scientific Director, Ludwig Institute for Cancer Research
Professor, The Wistar Institute

Scott Lippman, M.D.
Professor of Medicine, Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care, University of California, San Diego

Jeffrey Peppercorn, M.D., M.P.H.
Director, Cancer Survivorship Program, Massachusetts General Hospital
Associate Professor of Medicine at Harvard Medical School

Cliff Hudis, M.D., F.A.C.P.
Chief Executive Officer of the American Society of Clinical Oncology

Douglas Lowry, M.D.
Deputy Director, National Cancer Institute

Experts Discuss Future Cancer Research Priorities in the United States (Part 1)

Top scientists discuss how they recommend expanding and implementing the Blue Ribbon Panel’s road map for cancer research. They’ll discuss a report that will be published by the journal The Lancet Oncology and is co-edited by Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, and Chi Van Dang, M.D., Ph.D., scientific director at Ludwig Cancer Research and professor at The Wistar Institute.

Experts Discuss Future Cancer Research Priorities in the United States (Part 2)

Top scientists discuss how they recommend expanding and implementing the Blue Ribbon Panel’s road map for cancer research. They’ll discuss a report that will be published by the journal The Lancet Oncology and is co-edited by Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, and Chi Van Dang, M.D., Ph.D., scientific director at Ludwig Cancer Research and professor at The Wistar Institute.